See more : Kingsoft Corporation Limited (KSFTF) Income Statement Analysis – Financial Results
Complete financial analysis of Belite Bio, Inc (BLTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Belite Bio, Inc, a leading company in the Biotechnology industry within the Healthcare sector.
- Hawaiian Macadamia Nut Orchards, L.P. (NNUTU) Income Statement Analysis – Financial Results
- Wal-Mart de México, S.A.B. de C.V. (WMMVY) Income Statement Analysis – Financial Results
- Alantra Partners, S.A. (ALNT.MC) Income Statement Analysis – Financial Results
- Highland Copper Company Inc. (HDRSF) Income Statement Analysis – Financial Results
- Sensys Gatso Group AB (publ) (SENS.ST) Income Statement Analysis – Financial Results
Belite Bio, Inc (BLTE)
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 399.00K | 198.00K | 30.00K | 17.00K |
| Gross Profit | -399.00K | -198.00K | -30.00K | -17.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.84M | 8.87M | 7.42M | 3.69M |
| General & Administrative | 6.82M | 3.95M | 2.38M | 2.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.82M | 3.95M | 2.38M | 2.06M |
| Other Expenses | 0.00 | 166.00K | 126.00K | 0.00 |
| Operating Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Cost & Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Interest Income | 74.00K | 23.00K | 5.00K | 12.00K |
| Interest Expense | 25.00K | 16.00K | 0.00 | 21.00K |
| Depreciation & Amortization | 139.00K | 198.00K | 30.00K | 17.00K |
| EBITDA | -31.53M | -12.43M | -9.64M | -5.71M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.67M | -12.82M | -9.80M | -5.74M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.00K | 173.00K | 131.00K | -9.00K |
| Income Before Tax | -31.62M | -12.65M | -9.67M | -5.75M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 9.00K | -173.00K | 126.00K | 1.00K |
| Net Income | -31.63M | -12.48M | -9.79M | -5.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.19 | -0.62 | -0.41 | -0.24 |
| EPS Diluted | -1.19 | -0.62 | -0.41 | -0.24 |
| Weighted Avg Shares Out | 26.59M | 19.98M | 24.10M | 24.10M |
| Weighted Avg Shares Out (Dil) | 26.59M | 19.98M | 24.10M | 24.10M |
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
Belite Bio to Participate in the BTIG Ophthalmology Day
Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports